ERBB2 and breast carcinoma: There are no reports with regards to beneficial effects of CXCL-13 in ovarian cancer, however, links with improved outcome have been observed in HER2+ breast cancer patients.46 Combined with results of our study these associations suggest possible anti-tumor rather than tumor-promoting roles for IL-23 and CXCL-13 in the ovarian cancer context and warrant further investigation.